Merck buys rights to heart disease drug
Withdrawing renin-angiotensin inhibitors/angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists tied to higher one-year mortality, morbidity.
India Today on MSN10h
Combining two cholesterol-lowering drugs could reduce heart attack, stroke riskA new study has found that combining statins - the first-line treatment for high cholesterol - and ezetimibe, another drug ...
Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...
There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher ...
A new study from the University of Bologna has raised concerns about a common blood pressure medication called beta-blockers.
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...
Shrinking brain volumes have been linked to mild cognitive impairment and dementia, researchers noted. "This review shows ...
Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results